[1] YANAGI S, INATOME R, TAKANO T, et al. Syk expression and novel function in a wide variety of tissues. Biochem Biophys Res Commun. 2001;288(3):495-498.
[2] LOW SA, KOPECEK J. Targeting polymer therapeutics to bone. Adv Drug Deliv Rev. 2012;64(12):1189-204.
[3] CHEN X, WANG Z, DUAN N, et al. Osteoblast-osteoclast interactions. Connect Tissue Res. 2018;59(2):99-107.
[4] MOCSAI A, RULAND J, TYBULEWICZ VL. The SYK tyrosine kinase:a crucial player in diverse biological functions. Nat Rev Immunol. 2010;10(6):387-402.
[5] WANG L, DUKE L, ZHANG PS, et al. Alternative splicing disrupts a nuclear localization signal in spleen tyrosine kinase that is required for invasion suppression in breast cancer. Cancer Res. 2003;63(15):4724-4730.
[6] PALACIOS EH, WEISS A. Distinct roles for Syk and ZAP-70 during early thymocyte development. J Exp Med. 2007;204(7):1703-1715.
[7] ZIEGENFUSS JS, BISWAS R, AVERY MA, et al. Draper-dependent glial phagocytic activity is mediated by Src and Syk family kinase signalling. Nature. 2008;453(7197):935-939.
[8] AU-YEUNG BB, DEINDL S, HSU LY, et al. The structure, regulation, and function of ZAP-70. Immunol Rev. 2009;228(1):41-57.
[9] TURNER M, SCHWEIGHOFFER E, COLUCCI F, et al. Tyrosine kinase SYK: essential functions for immunoreceptor signalling. Immunol Today. 2000;21(3):148-154.
[10] FLORENCIO-SILVA R, SASSO GR, SASSO-CERRI E, et al. Biology of bone tissue: structure, function, and factors that influence bone cells. Biomed Res Int. 2015; 2015:421746.
[11] ROSS FP, CHRISTIANO AM. Nothing but skin and bone. J Clin Invest. 2006;116(5): 1140-1149.
[12] SHI C, WU T, HE Y, et al. Recent advances in bone-targeted therapy. Pharmacol Ther. 2020;207:107473.
[13] CLARKE B. Normal bone anatomy and physiology. Clin J Am Soc Nephrol. 2008;3 Suppl 3:S131-S139.
[14] LEE K, SEO I, CHOI MH, et al. Roles of mitogen-activated protein kinases in osteoclast biology. Int J Mol Sci. 2018;19(10):3004.
[15] SOBACCHI C, SCHULZ A, COXON FP, et al. Osteopetrosis: genetics, treatment and new insights into osteoclast function. Nat Rev Endocrinol. 2013;9(9):522-536.
[16] RACHNER TD, KHOSLA S, HOFBAUER LC. Osteoporosis:now and the future. The Lancet. 2011;377(9773):1276-1287.
[17] SCHETT G, GRAVALLESE E. Bone erosion in rheumatoid arthritis:mechanisms, diagnosis and treatment. Nat Rev Rheumatol. 2012;8(11):656-664.
[18] LE GOFF B, BERTHELOT JM, MAUGARS Y, et al. Osteoclasts in RA: diverse origins and functions. Joint Bone Spine. 2013;80(6):586-591.
[19] EDWARDS JR, MUNDY GR. Advances in osteoclast biology:old findings and new insights from mouse models. Nat Rev Rheumatol. 2011;7(4):235-243.
[20] OKAMOTO K, NAKASHIMA T, SHINOHARA M, et al. Osteoimmunology: the conceptual framework unifying the immune and skeletal systems. Physiol Rev. 2017;97(4):1295-1349.
[21] TAKAYANAGI H. New immune connections in osteoclast formation. Ann N Y Acad Sci. 2010;1192:117-123.
[22] GYORI DS, MOCSAI A. Osteoclast signal transduction during bone metastasis formation. Front Cell Dev Biol. 2020;8:507.
[23] TAKAYANAGI H. Osteoimmunology: shared mechanisms and crosstalk between the immune and bone systems. Nat Rev Immunol. 2007;7(4):292-304.
[24] ABTAHIAN F, GUERRIERO A, SEBZDA E, et al. Regulation of blood and lymphatic vascular separation by signaling proteins SLP-76 and Syk. Science. 2003;299(5604): 247-251.
[25] CSETE D, SIMON E, ALATSHAN A, et al. Hematopoietic or osteoclast-specific deletion of syk leads to increased bone mass in experimental mice. Front Immunol. 2019;10:937.
[26] NAKAMURA T, IMAI Y, MATSUMOTO T, et al. Estrogen prevents bone loss via estrogen receptor alpha and induction of Fas ligand in osteoclasts. Cell. 2007; 130(5):811-823.
[27] ZOU W, KITAURA H, REEVE J, et al. Syk, c-Src, the alphavbeta3 integrin, and ITAM immunoreceptors, in concert, regulate osteoclastic bone resorption. J Cell Biol. 2007;176(6):877-888.
[28] MOCSAI A, HUMPHREY MB, VAN ZIFFLE JA, et al. The immunomodulatory adapter proteins DAP12 and Fc receptor gamma-chain (FcRgamma) regulate development of functional osteoclasts through the Syk tyrosine kinase. Proc Natl Acad Sci U S A. 2004;101(16):6158-6163.
[29] LEE EJ, KIM JL, GONG JH, et al. Inhibition of osteoclast activation by phloretin through disturbing alphavbeta3 integrin-c-Src pathway. Biomed Res Int. 2015; 2015:680145.
[30] FACCIO R, TEITELBAUM SL, FUJIKAWA K, et al. Vav3 regulates osteoclast function and bone mass. Nat Med. 2005;11(3):284-290.
[31] LAU KW, SHENG MH. A novel miR17/protein tyrosine phosphatase-oc/EphA4 regulatory axis of osteoclast activity. Arch Biochem Biophys. 2018;650:30-38.
[32] TAIRA T, SAITO Y, NIKI T, et al. DJ-1 has a role in antioxidative stress to prevent cell death. E Rep. 2004;5(2):213-218.
[33] KIM HS, NAM ST, MUN SH, et al. DJ-1 controls bone homeostasis through the regulation of osteoclast differentiation. Nat Commun. 2017;8(1):1519.
[34] CAI X, XING J, LONG CL, et al. DOK3 Modulates bone remodeling by negatively regulating osteoclastogenesis and positively regulating osteoblastogenesis. J Bone Miner Res. 2017;32(11):2207-2218.
[35] PERUZZI G, MOLFETTA R, GASPARRINI F, et al. The adaptor molecule CIN85 regulates Syk tyrosine kinase level by activating the ubiquitin-proteasome degradation pathway. J Immunol. 2007;179(4):2089-2096.
[36] KIM JY, PARK SH, BAEK JM, et al. Harpagoside Inhibits RANKL-Induced Osteoclastogenesis via Syk-Btk-PLCgamma2-Ca(2+) Signaling Pathway and Prevents Inflammation-Mediated Bone Loss. J Nat Prod. 2015;78(9):2167-2174.
[37] HARA S, NAGAI-YOSHIOKA Y, YAMASAKI R, et al. Dectin-1-mediated suppression of RANKL-induced osteoclastogenesis by glucan from baker’s yeast. J Cell Physiol. 2020; 236(7):5098-5107.
[38] WAGENER M, HOVING JC, NDLOVU H, et al. Dectin-1-Syk-CARD9 signaling pathway in TB immunity. Front Immunol. 2018;9:225.
[39] FUJITA S, MUKAI T, MITO T, et al. Pharmacological inhibition of tankyrase induces bone loss in mice by increasing osteoclastogenesis. Bone. 2018;106:156-166.
[40] KIM MK, KIM B, KWON JO, et al. ST5 positively regulates osteoclastogenesis via Src/Syk/calcium signaling pathways. Mol Cells. 2019;42(11):810-819.
[41] JIA Y, TAO Y, LV C, et al. Tetrandrine enhances the ubiquitination and degradation of Syk through an AhR-c-src-c-Cbl pathway and consequently inhibits osteoclastogenesis and bone destruction in arthritis. Cell Death Dis. 2019;10(2): 38.
[42] JIA Y, MIAO Y, YUE M, et al. Tetrandrine attenuates the bone erosion in collagen-induced arthritis rats by inhibiting osteoclastogenesis via spleen tyrosine kinase. FASEB J. 2018;32(6):3398-3410.
[43] VAZQUEZ-GOMEZ G, ROCHA-ZAVALETA L, RODRIGUEZ-SOSA M, et al. Benzo[a]pyrene activates an AhR/Src/ERK axis that contributes to CYP1A1 induction and stable DNA adducts formation in lung cells. Toxicol Lett. 2018;289:54-62.
[44] LEE B, IWANIEC UT, TURNER RT, et al. RIP140 in monocytes/macrophages regulates osteoclast differentiation and bone homeostasis. JCI Insight. 2017;2(7):e90517.
[45] GUNTUR AR, ROSEN CJ. The skeleton:a multi-functional complex organ:new insights into osteoblasts and their role in bone formation: the central role of PI3Kinase. J Endocrinol. 2011;211(2):123-130.
[46] CHAVES NETO AH, QUEIROZ KC, MILANI R, et al. Profiling the changes in signaling pathways in ascorbic acid/beta-glycerophosphate-induced osteoblastic differentiation. J Cell Biochem. 2011;112(1):71-77.
[47] SU CM, CHIANG YC, HUANG CY, et al. Osteopontin promotes oncostatin m production in human osteoblasts:implication of rheumatoid arthritis therapy. J Immunol. 2015;195(7):3355-3364.
[48] PACIFICI R. The role of IL-17 and TH17 cells in the bone catabolic activity of PTH. Front Immunol. 2016;7:57.
[49] TSAI CH, LIU SC, WANG YH, et al. Osteopontin inhibition of miR-129-3p enhances IL-17 expression and monocyte migration in rheumatoid arthritis. Biochim Biophys Acta Gen Subj. 2017;1861(2):15-22.
[50] YOSHIDA K, HIGUCHI C, NAKURA A, et al. Spleen tyrosine kinase suppresses osteoblastic differentiation through MAPK and PKCα. Biochem Biophys Res Commun. 2011;411(4):774-779.
[51] KUSUYAMA J, KAMISONO A, CHANGHWAN S, et al. Spleen tyrosine kinase influences the early stages of multilineage differentiation of bone marrow stromal cell lines by regulating phospholipase C gamma activities. J Cell Physiol. 2018;233(3):2549-2559.
[52] MAZHARIAN A, THOMAS SG, DHANJAL TS, et al. Critical role of Src-Syk-PLC{gamma}2 signaling in megakaryocyte migration and thrombopoiesis. Blood. 2010;116(5):793-800.
[53] GOETZKE R, SECHI A, DE LAPORTE L, et al. Why the impact of mechanical stimuli on stem cells remains a challenge. Cell Mol Life Sci. 2018;75(18):3297-3312.
[54] KUSUYAMA J, SEONG C, MAKAREWICZ NS, et al. Low intensity pulsed ultrasound (LIPUS) maintains osteogenic potency by the increased expression and stability of Nanog through spleen tyrosine kinase (Syk) activation. Cell Signal. 2019;62: 109345.
[55] BOYLE ST, SAMUEL MS. Mechano-reciprocity is maintained between physiological boundaries by tuning signal flux through the Rho-associated protein kinase. Small GTPases. 2016;7(3):139-146.
[56] KUSUYAMA J, NAKAMURA T, OHNISHI T, et al. Low-intensity pulsed ultrasound promotes bone morphogenic protein 9-induced osteogenesis and suppresses inhibitory effects of inflammatory cytokines on cellular responses via Rho-associated kinase 1 in human periodontal ligament fibroblasts. J Cell Biochem. 2019;120(9):14657-14669.
[57] MUKAI T, ISHIDA S, ISHIKAWA R, et al. SH3BP2 cherubism mutation potentiates TNF-alpha-induced osteoclastogenesis via NFATc1 and TNF-alpha-mediated inflammatory bone loss. J Bone Miner Res. 2014;29(12):2618-2635.
[58] TAN RZ, LI JC, LIU J, et al. BAY61-3606 protects kidney from acute ischemia/reperfusion injury through inhibiting spleen tyrosine kinase and suppressing inflammatory macrophage response. FASEB J. 2020. doi: 10.1096/fj.202000261RRR.
[59] TAN RZ, WANG C, DENG C, et al. Quercetin protects against cisplatin-induced acute kidney injury by inhibiting Mincle/Syk/NF-kappaB signaling maintained macrophage inflammation. Phytother Res. 2020;34(1):139-152.
[60] 陈玉凤.Syk介导的JNK和NLRP3的活化在糖尿病心肌病中的作用的研究[D]. 天津:天津医科大学,2017.
[61] PANDORI WJ, LIMA TS, MALLYA S, et al. Toxoplasma gondii activates a Syk-CARD9-NF-kappaB signaling axis and gasdermin D-independent release of IL-1beta during infection of primary human monocytes. PLoS Pathog. 2019;15(8):e1007923.
[62] LIU D, ZENG X, LI X, et al. Advances in the molecular mechanisms of NLRP3 inflammasome activators and inactivators. Biochem Pharmacol. 2020;175:113863.
[63] ALLAEYS I, MARCEAU F, POUBELLE PE. NLRP3 promotes autophagy of urate crystals phagocytized by human osteoblasts. Arthritis Res Ther. 2013;15(6):R176.
[64] MATSUMOTO Y, ROTTAPEL R. Bone dynamics and inflammation: lessons from rare diseases. Immunol Med. 2020;43(2):61-64.
[65] YOSHIMOTO T, HAYASHI T, KONDO T, et al. Second-generation syk inhibitor entospletinib ameliorates fully established inflammation and bone destruction in the cherubism mouse model. J Bone Miner Res. 2018;33(8):1513-1519.
[66] CHARLES-SCHOEMAN C, BURMESTER G, NASH P, et al. Efficacy and safety of tofacitinib following inadequate response to conventional synthetic or biological disease-modifying antirheumatic drugs. Ann Rheum Dis. 2016;75(7):1293-1301.
[67] LLOP-GUEVARA A, PORRAS M, CENDON C, et al. Simultaneous inhibition of JAK and SYK kinases ameliorates chronic and destructive arthritis in mice. Arthritis Res Ther. 2015;17:356.
[68] MATSUMOTO I, ZHANG H, YASUKOCHI T, et al. Therapeutic effects of antibodies to tumor necrosis factor-alpha, interleukin-6 and cytotoxic T-lymphocyte antigen 4 immunoglobulin in mice with glucose-6-phosphate isomerase induced arthritis. Arthritis Res Ther. 2008;10(3):R66.
|